Drugmaker Shire offers to buy Baxalta for US$30b

London

IRISH drugmaker Shire said on Tuesday that it had offered to buy the biopharmaceutical company Baxalta in an all-stock deal worth about US$30 billion.

Shire said on Tuesday that it had approached Baxalta in early July about a potential combination, but Baxalta concluded, following a written proposal on July 31, not to proceed with discussions.